Effectiveness of once-daily high-dose ACTH for infantile spasms

Ryan M Hodgeman1, Kush Kapur1, Ann Paris1

  • 1Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

Insights

Once-daily high-dose adrenocorticotropic hormone (ACTH) is effective for treating infantile spasms (IS), with 70% of infants becoming spasm-free within 14 days. This simplified dosing schedule is comparable to twice-daily treatments.

Area of Science:

  • Pediatric Neurology
  • Endocrinology

Background:

  • Infantile spasms (IS) treatment lacks standardized protocols, leading to varied institutional practices.
  • Current recommendations often involve twice-daily high-dose adrenocorticotropic hormone (ACTH), as suggested by the National Infantile Spasms Consortium (NISC).

Purpose of the Study:

  • To evaluate the effectiveness and tolerability of a once-daily high-dose ACTH dosing protocol for infantile spasms.
  • To compare the outcomes of once-daily ACTH administration with existing literature on twice-daily dosing.

Main Methods:

  • Retrospective review of 57 infantile spasms cases treated with once-daily high-dose ACTH at Boston Children's Hospital over four years.
  • Meta-analysis comparing the center's results with published data on twice-daily high-dose ACTH treatment for IS.

Main Results:

  • 70% of infants achieved spasm freedom at 14 days post-ACTH initiation.
  • 54% of infants remained spasm-free at 3-month follow-up.
  • Electroencephalogram (EEG) showed hypsarrhythmia resolution in all responders; once-daily ACTH was well-tolerated.

Conclusions:

  • Once-daily high-dose ACTH is an effective treatment for infantile spasms.
  • This dosing regimen offers comparable efficacy to twice-daily administration, potentially simplifying treatment and reducing patient burden.
  • Further prospective trials are warranted to confirm these findings and support a standardized protocol.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
713
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.9K
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
2.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
613
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K